Methodology: 3.5/5
Usefulness: 4/5

Davenport R, et al. JAMA. 2023 Oct 12:e2321019. 

Editorial: Contemporary Adjuncts to Hemorrhage Control.

Question and Methods: In trauma patients with major hemorrhage, does early cryoprecipitate (6g fibrinogen) administration improve survival, compared to standard care?
Findings: There was no difference in all-cause mortality at 28 days (25.35 vs. 26.1%); OR 0.96 [95% CI 0.75-1.23] p=0.74
Limitations: Cross over between groups (15% of cryoprecipitate group didn’t receive any, 9% of control group received cryoprecipitate within 90mins) though per protocol analysis this didn’t impact the results.

Interpretation: Addition of early and empiric cryoprecipitate to standard care among adult trauma patients with major hemorrhage protocol activation, did not improve all cause 28-day mortality.

By: Dr. Mejbel Alazemi

JC Supervisor: Dr. Venkatesh Thiruganasambandamoorthy